Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020.

ABSTRACT: The survival rate of multiple myeloma (MM) patients has drastically increased recently as a result of the wide treatment options now available. Younger patients truly benefit from these innovations as they can support more intensive treatment, such as autologous stem cell transplant or multiple drug association (triplet, quadruplet). The emergence of immunotherapy allowed new combinations principally based on monoclonal anti-CD38 antibodies for these patients. Still, the optimal induction treatment has not been found yet. While consolidation is still debated, maintenance treatment is now well acknowledged to prolong survival. Lenalidomide monotherapy is the only drug approved in that setting, but many innovations are expected. Older patients, now logically named not transplant-eligible, al

SUBMITTER: Bobin A 

PROVIDER: S-EPMC7600346 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature